{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T04:03:20Z","timestamp":1745294600795,"version":"3.40.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,21]]},"DOI":"10.7759\/cureus.82707","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:53:22Z","timestamp":1745250802000},"source":"Crossref","is-referenced-by-count":0,"title":["Late-Onset Autoimmune Myasthenia Gravis: A Diagnosis Not to Be Overlooked in the Elderly"],"prefix":"10.7759","author":[{"given":"Abrar-Ahmad","family":"Zulfiqar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015, 22:17-23. 10.1111\/ene.12599","journal-title":"Eur J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell LC","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011, 1:16-22. 10.1177\/1941875210382918","journal-title":"Neurohospitalist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.02.013","article-title":"Clinical characteristics and prognosis of very late-onset myasthenia gravis in China","volume":"33","author":"Tang YL","year":"2023","unstructured":"Tang YL, Ruan Z, Su Y, et al.. Clinical characteristics and prognosis of very late-onset myasthenia gravis in China. Neuromuscul Disord. 2023, 33:358-66. 10.1016\/j.nmd.2023.02.013","journal-title":"Neuromuscul Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJ. Myasthenia gravis. Nat Rev Dis Primers. 2019, 5:30. 10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza R","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018, 11:1756285617749134. 10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami P","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al.. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021, 96:114-22. 10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-4598(200004)23:4<453::aid-mus3>3.0.co;2-o","article-title":"Acetylcholine receptors and myasthenia","volume":"23","author":"Lindstrom JM","year":"2000","unstructured":"Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000, 23:453-77. 10.1002\/(sici)1097-4598(200004)23:4&lt;453::aid-mus3&gt;3.0.co;2-o","journal-title":"Muscle Nerve"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith MJ","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003, 60:243-8. 10.1001\/archneur.60.2.243","journal-title":"Arch Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie GO","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, et al.. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010, 17:893-902. 10.1111\/j.1468-1331.2010.03019.x","journal-title":"Eur J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277.pub4","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos P","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012, 12:002277. 10.1002\/14651858.CD002277.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26876","article-title":"Rituximab in late-onset myasthenia gravis is safe and effective","volume":"62","author":"Sahai SK","year":"2020","unstructured":"Sahai SK, Maghzi AH, Lewis RA. Rituximab in late-onset myasthenia gravis is safe and effective. Muscle Nerve. 2020, 62:377-380. 10.1002\/mus.26876","journal-title":"Muscle Nerve"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/360810-late-onset-autoimmune-myasthenia-gravis-a-diagnosis-not-to-be-overlooked-in-the-elderly","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:53:23Z","timestamp":1745250803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/360810-late-onset-autoimmune-myasthenia-gravis-a-diagnosis-not-to-be-overlooked-in-the-elderly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.82707","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}